Curanex Pharmaceuticals (CURX) Liabilities and Shareholders Equity (2024 - 2025)
Curanex Pharmaceuticals' (CURX) quarterly Liabilities and Shareholders Equity came in at $11.6 million in Q4 2025, up 2135.83% YoY from $517935.0 in Q4 2024, and down 20.02% on a QoQ basis from $14.5 million in Q3 2025.
Curanex Pharmaceuticals (CURX) Liabilities and Shareholders Equity (2024 - 2025) Analysis & Trends
Curanex Pharmaceuticals (CURX) has 2 years of Liabilities and Shareholders Equity data on file, last reported at $11.6 million in Q4 2025.
- Quarterly Liabilities and Shareholders Equity rose 2135.83% year-over-year to $11.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $27.4 million (changed N/A YoY) and the FY2025 annual result came in at $11.6 million, up 2135.83% from the prior year.
- Liabilities and Shareholders Equity fell to $11.6 million in Q4 2025, from $14.5 million in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $14.5 million in Q3 2025 to a low of $517935.0 in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.56 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.60 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.10 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | Curanex Pharmaceuticals | 6.02 Mn | 1.02 Mn | - | 11.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 11.58 Mn |
| Sep 30, 2025 | 14.48 Mn |
| Jun 30, 2025 | 787,174.00 |
| Dec 31, 2024 | 517,935.00 |